Melanoma
Point Biopharma to Launch Phase I Study of FAP-Targeted Radiopharmaceutical in Canada
The first-in-human study is designed to assess both the gallium-68-labeled imaging agent and the lutetium-177-labeled therapeutic in five solid cancer types.
OncoHost Raises $35M in Series C Financing
The Israeli firm will use the funds to expand its PROPHETIC trial and support the US commercial launch of the Prophet platform.
Castle Biosciences, VHA Expand Supply Contract to Cover Full Skin Cancer Test Portfolio
The new contract with the Veterans Health Administration makes all five of the company's skin cancer assays available for veterans, active-duty military, and family members.
Multiple successor trials are in the works based on hits, misses, and overall knowledge gained from one of the first precision medicine platform trials.
Iovance Biotherapeutics Receives Positive FDA Feedback Supporting Lifileucel BLA Submission
The firm said regulators support its new potency assay matrix and that it will file for lifileucel approval for metastatic melanoma this August.